Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes*

By He Yan-Ling   Sabo Ron   Picard Franck   Wang Yibin   Herron Jerry   Ligueros-Saylan Monica   Dole William P.  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1265-1272

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany

By Göke R.   Gruenberger J. B.   Bader G.   Dworak M.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 785-789

Informa Healthcare

Access to resources Recommend Favorite

Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 292-300

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan

By Hanif W.  

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 807-811

Informa Healthcare

Access to resources Recommend Favorite